These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29770170)

  • 21. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic therapies for hepatocellular carcinoma: the present and the future.
    Celsa C; Giuffrida P; Stornello C; Grova M; Spatola F; Rizzo GEM; Busacca A; Cannella R; Battaglia S; Cammà C; Cabibbo G
    Recenti Prog Med; 2021 Feb; 112(2):110-116. PubMed ID: 33624623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapies for hepatocellular carcinoma.
    Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
    Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma.
    Trojan J; Waidmann O
    J Hepatocell Carcinoma; 2016; 3():31-36. PubMed ID: 27703962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond.
    Amaro CP; Tam VC
    Curr Oncol; 2020 Nov; 27(Suppl 3):S173-S180. PubMed ID: 33343211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and Future Systemic Therapies for Hepatocellular Carcinoma.
    Bteich F; Di Bisceglie AM
    Gastroenterol Hepatol (N Y); 2019 May; 15(5):266-272. PubMed ID: 31360140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment.
    Kim BH; Park JW
    J Liver Cancer; 2021 Sep; 21(2):124-138. PubMed ID: 37383078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current options and future possibilities for the systemic treatment of hepatocellular carcinoma.
    Raoul JL; Frenel JS; Raimbourg J; Gilabert M
    Hepat Oncol; 2019 Jun; 6(1):HEP11. PubMed ID: 31244990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HCC and Molecular Targeting Therapies: Back to the Future.
    Rinaldi L; Vetrano E; Rinaldi B; Galiero R; Caturano A; Salvatore T; Sasso FC
    Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging agents and regimens for hepatocellular carcinoma.
    Zhu XD; Sun HC
    J Hematol Oncol; 2019 Oct; 12(1):110. PubMed ID: 31655607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic Treatment for Advanced Hepatocellular Carcinoma.
    Bouattour M; Mehta N; He AR; Cohen EI; Nault JC
    Liver Cancer; 2019 Oct; 8(5):341-358. PubMed ID: 31768344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
    Lee MMP; Chan LL; Chan SL
    J Liver Cancer; 2023 Sep; 23(2):262-271. PubMed ID: 37589044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.
    Mody K; Abou-Alfa GK
    Curr Treat Options Oncol; 2019 Jan; 20(2):3. PubMed ID: 30635732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies.
    Marquardt JU; Saborowski A; Czauderna C; Vogel A
    Target Oncol; 2019 Apr; 14(2):115-123. PubMed ID: 30805831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
    Raoul JL; Kudo M; Finn RS; Edeline J; Reig M; Galle PR
    Cancer Treat Rev; 2018 Jul; 68():16-24. PubMed ID: 29783126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.
    Luo XY; Wu KM; He XX
    J Exp Clin Cancer Res; 2021 May; 40(1):172. PubMed ID: 34006331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
    Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy in Advanced Hepatocellular Carcinoma.
    Javan H; Dayyani F; Abi-Jaoudeh N
    Semin Intervent Radiol; 2020 Dec; 37(5):466-474. PubMed ID: 33328702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life.
    Li D; Sedano S; Allen R; Gong J; Cho M; Sharma S
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31216701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.